PRINCETON, N.J., July 28, 2024 /PRNewswire/ — Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ERZOFRI® (paliperidone palmitate) extended-release injectable suspension, for treating schizophrenia in adults and for treating schizoaffective […]
Category Archives: Pr Newswire
Pr Newswire
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
28
Jul
Jul
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients […]
SHANGHAI, July 28, 2024 /PRNewswire/ — On 26 July 2024, the DreamSmart AI Ecological Pavilion officially landed at the 2024 China International Digital Interactive Entertainment Exhibition (2024 ChinaJoy, Shanghai • New International Expo Center Snapdragon Theme Pavilion E4-05 Booth), presenting the latest AI intelligent technology products and multi-field ecological achievements in a new integrated exhibition format […]
The Beijing Central Axis is now ready for digital visitors from around the world SHENZHEN, China, July 27, 2024 /PRNewswire/ — Tencent (0700.HK) today launched the largest virtual urban historical landscape created to date called Microcosm, an immersive experience that brings Beijing’s Central Axis to life online. The project launch coincides with the addition of the […]
27
Jul
Jul
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024, […]
Pr Newswire
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Second Quarter 2024 Financial Results on August 1, 2024
27
Jul
Jul
FREDERICK, Md., July 26, 2024 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 1, 2024, and will hold a conference […]
Pr Newswire
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
27
Jul
Jul
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” […]
Pr Newswire
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
27
Jul
Jul
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes […]
Pr Newswire
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
27
Jul
Jul
Company to host conference call on Monday, July 29 at 8:30 a.m. ET NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density […]
27
Jul
Jul
Publication of the 2024 Interim Financial Report Paris, France (July 26, 2024 – 6:30 pm) – The Board of Directors of EssilorLuxottica met on July 25, 2024 to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2024. EssilorLuxottica’s 2024 Interim Financial Report has been published today. The Interim Financial […]